Valeo Pharma (TSE:VPH) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Valeo Pharma Inc. has revised its credit agreement with Sagard Healthcare Royalty Partners, extending the due date for an initial $10 million payment and reducing its loan principal by approximately C$6.5 million. The amendment offers Valeo Pharma enhanced financial flexibility to pursue its strategic plans. The company focuses on the commercialization of specialty pharmaceuticals in Canada.
For further insights into TSE:VPH stock, check out TipRanks’ Stock Analysis page.